


7. 1H-indazole-3-carboxamide compounds according to claim 6, wherein Y is a C₁-C₃ alkyl group.
8. 1H-indazole-3-carboxamide compounds according to claim anyone of the preceding claims, wherein R_b is a C₁-C₆ alkoxy group; -C(O)OH; -C(O)OR₁; -NHCOR₁.
9. 1H-indazole-3-carboxamide compounds according to claim 8, wherein R_b is a C₁-C₆ alkoxy group; -C(O)OH.
10. 1H-indazole-3-carboxamide compounds according to claim 9, wherein R_b is a C₁-C₃ alkoxy group, -C(O)OH.
11. 1H-indazole-3-carboxamide compounds according to claim anyone of the preceding claims, wherein R₁ and R₂ are independently a C₁-C₃ alkyl group.
- ~~12. Use of 1H-indazole-3-carboxamide compounds having the following general formula (I)~~



wherein

- ~~R_a and R_{a'}, equal or different each other, is a hydrogen atom; a halogen atom; a hydroxy group; a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl and C₁-C₆ alkoxy group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, -NH₂, and C₁-C₃ alkoxy; a carbocyclic or heterocyclic ring, aliphatic or aromatic, having from 3 to 12 members, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, -NR₁R₂, -C(O)OH, -C(O)OR₁ and -C(O)NR₁R₂;~~

~~Y is a bond, a C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, -NH₂, and C₁-C₃ alkoxy;~~

~~R_b is a C₁-C₆ alkoxy group; -C(O)OH; -C(O)OR₄; -NO₂; -NHC(O)R₄;~~

5 ~~R₁ and R₂ are independently a hydrogen atom, a C₁-C₄ alkyl group, a C₂-C₄ alkenyl group, a C₂-C₄ alkynyl group, and a phenyl group; and its salts of addition with pharmaceutically acceptable organic and inorganic acids and bases;~~

10 ~~for the treatment of a disease arising from the uncontrolled activation and/or overexpression of GSK-3 β , selected from the group consisting of (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; (viii) epilepsies; and (ix) neuropathic pain.~~

15 ~~13. The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said insulin-resistance disorders are selected from the group consisting of type-2 diabetes, syndrome X, obesity and polycystic ovary syndrome.~~

20 ~~14. The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said neurodegenerative diseases are selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, and spinal neurodegenerative disorders.~~

25 ~~15. The use of a 1H-indazole-3-carboxamide according to claim 14, wherein said spinal neurodegenerative disorders are selected from the group consisting of amyotrophic lateral sclerosis, multiple sclerosis, spinal muscular atrophy and neurodegeneration due to spinal cord injury.~~

30 ~~16. The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said mood disorders are selected from the group consisting of bipolar disorders and depressive disorders.~~

17. ~~The use of a 1H-indazole-3-carboxamide according to claim 16, wherein said bipolar disorders are selected from the group consisting of bipolar I, bipolar II, cyclothymia and bipolar disorder not otherwise specified (BD-NOS).~~
- 5 18. ~~The use of a 1H-indazole-3-carboxamide according to claim 16, wherein said depressive disorders are selected from the group consisting of major depressive disorder (MDD), atypical depression (AD), melancholic depression, psychotic major depression (PMD), catatonic depression, postpartum depression (PPD), seasonal~~
10 ~~affective disorder (SAD), dysthymia, and depressive disorder not otherwise specified (DD-NOS).~~
19. ~~The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said substance abuse disorders are selected from the group of abuse disorders due to psychostimulants.~~
- 15 20. ~~The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said schizophrenic disorders are selected from the group consisting of paranoid schizophrenia, disorganized schizophrenia, catatonic schizophrenia, simple schizophrenia, residual schizophrenia, and undifferentiated schizophrenia.~~
- 20 21. ~~The use of a 1H-indazole-3-carboxamide according to claim 12, wherein said cancerous disorders are selected from the group consisting of prostate, pancreatic, ovarian, and colon-rectal cancer and MLL-associated leukaemia.~~
- 25 22. A pharmaceutical composition comprising an effective amount of at least one compound of formula (I) as defined in anyone of claims 1-11 above, a salt thereof with a pharmaceutically acceptable organic or inorganic acid or base and at least one inert pharmaceutically acceptable excipient.

7. 1H-indazole-3-carboxamide compounds according to claim 6, wherein Y is a C₁-C₃ alkyl group.
8. 1H-indazole-3-carboxamide compounds according to claim anyone of the preceding claims, wherein R_b is a C₁-C₆ alkoxy group; -C(O)OH;
5 -C(O)OR₁; -NHCOR₁.
9. 1H-indazole-3-carboxamide compounds according to claim 8, wherein R_b is a C₁-C₆ alkoxy group; -C(O)OH.
10. 1H-indazole-3-carboxamide compounds according to claim 9, wherein R_b is a C₁-C₃ alkoxy group, -C(O)OH.
- 10 11. 1H-indazole-3-carboxamide compounds according to claim anyone of the preceding claims, wherein R₁ and R₂ are independently a C₁-C₃ alkyl group.
12. A pharmaceutical composition comprising an effective amount of at
15 least one compound of formula (I) as defined in anyone of claims 1-11 above, a salt thereof with a pharmaceutically acceptable organic or inorganic acid or base and at least one inert pharmaceutically acceptable excipient.